Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Research & Development is the aggregate amount of research and development expenses during the year. Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Research & Development for the
three
months ended in Mar. 2026 was ₺0.0 Mil.
Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₺0.0 Mil.
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) Research & Development Explanation
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Research & Development Related Terms
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Research & Development Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Research & Development Chart
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Annual Data
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Research & Development Calculation
This is the expense the company spent on research and development.
Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Research & Development of ₺0.0 Mil mean?
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) has a Research & Development of ₺0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve and its competitors.
Is Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Research & Development too high?
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's current Research & Development is ₺0.0 Mil. Overall, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Research & Development compare to ABT and SYK?
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Research & Development of ₺0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve and its competitors. Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's current Research & Development is ₺0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve stock overvalued right now?
Based on GuruFocus' analysis, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) is currently considered Possible Value Trap. The stock's GF Value™ is ₺18.66, compared to a current price of ₺10.19 — trading 45.4% below its estimated fair value. The current Research & Development is ₺0.0 Mil. Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN), the current Research & Development is ₺0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve stock appears to be undervalued.
The current stock price of ₺10.19 is trading 45.4% below its estimated GF Value™ of ₺18.66.
GuruFocus considers Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve to be Possible Value Trap.
Key valuation signals for IST:ANGEN:
Research & Development: ₺0.0 Mil
GF Value™: ₺18.66 vs. price of ₺10.19 (45.4% below fair value)
No single metric tells the full story. See the IST:ANGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Business Description
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi Ve Ticaret AS is an international biotechnology company. It is engaged in designing, developing, and manufacturing Real-Time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments. It also manufactures NA Extraction kits, Microbiology kits, Genetic Disorders kits, Panel kits, Sequencing kits, Food Testing kits.
58GF Score
Get the complete analysis for IST:ANGEN
Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:ANGEN has been successfully added to your 
